Intermediate and Long Term Vascular Effects of Cisplatin in Patients With Testicular Cancer
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- venous occlusion plethysmography assessment of endothelial function
研究概览
简要总结
Chemotherapy drugs improve cancer survival but increase the risk of cardiovascular disease (CVD). VEGF inhibitors (VEGFI) cause severe hypertension, while cisplatin appears pro-thrombotic. Hence while cancer survival may improve, this is at the risk of potentially severe CVD and associated morbidity. Mechanisms underlying the cardiovascular toxicities of VEGFI and cisplatin are unknown, but effects on vascular function may be important.
The INTELLECT study will phenotype the endothelial effects of VEGFI and cisplatin using a variety of methods.
详细描述
There remains an unmet need to identify a preventive treatment for patients with testicular cancer treated with platinum based chemotherapy to diminish the risk of subsequent cardiovascular events. A future randomised trial of statin therapy in these patients is under consideration and results from this study will inform its design.
The information gained from this pilot study will guide the development of interventional pharmacological studies that are directed towards the most appropriate pathophysiological processes, at the most appropriate time and in the most appropriate patient groups treated with platinum based chemotherapy for testicular cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of stage 1 low-risk germ cell testicular cancer treated with orchidectomy, or IGCCC good or intermediate prognosis metastatic testicular/retroperitoneal germ cell cancer treated with orchidectomy (and or retroperitoneal surgery) plus cisplatin based chemotherapy, 12 - 18 months or 5 - 7 years previously.
- •Aged between 18 and 50 years inclusive, at time of enrolment
排除标准
- •Unable to provide written, informed consent
- •Unable or unwilling to attend for investigations
- •Current active involvement in a clinical trial
- •Those receiving drug treatment for any vascular disease:
- •o Including hypertension, hyperlipidaemia, cerebrovascular disease, ischaemic heart disease or heart failure
- •Chronic obstructive pulmonary disease
- •Diabetes mellitus
- •Arial fibrillation/flutter
- •Oral anticoagulation therapy
- •Cigarette smoker or tobacco use
- •Recreational drug use
- •Ongoing inflammatory, infective or autoimmune disease
- •Other malignant disease diagnosed in previous 7 years
- •Previous venous or arterial thrombotic/thromboembolic event
结局指标
主要结局
venous occlusion plethysmography assessment of endothelial function
时间窗: 8 weeks
expressed as ml per 100 ml of forearm volume per minute
次要结局
未报告次要终点